1
|
Pedersen RS, Nissen NI, Jensen C, Thorlacius-Ussing J, Manon-Jensen T, Olesen ML, Langholm LL, Diab HMH, Jorgensen LN, Hansen CP, Chen IM, Johansen JS, Karsdal MA, Willumsen N. Plasma Kallikrein-Activated TGF-β Is Prognostic for Poor Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma and Associates with Increased Fibrogenesis. Biomolecules 2022; 12:biom12091315. [PMID: 36139154 PMCID: PMC9496221 DOI: 10.3390/biom12091315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 09/12/2022] [Accepted: 09/15/2022] [Indexed: 11/16/2022] Open
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a hard-to-treat cancer due to the collagen-rich (fibrotic) and immune-suppressed microenvironment. A major driver of this phenomenon is transforming growth factor beta (TGF-β). TGF-β is produced in an inactive complex with a latency-associated protein (LAP) that can be cleaved by plasma kallikrein (PLK), hereby releasing active TGF-β. The aim of this study was to evaluate LAP cleaved by PLK as a non-invasive biomarker for PDAC and tumor fibrosis. An ELISA was developed for the quantification of PLK-cleaved LAP-TGF-β in the serum of 34 patients with PDAC (stage 1−4) and 20 healthy individuals. Biomarker levels were correlated with overall survival (OS) and compared to serum type III collagen (PRO-C3) and type VI collagen (PRO-C6) pro-peptides. PLK-cleaved LAP-TGF-β was higher in patients with PDAC compared to healthy individuals (p < 0.0001). High levels (>median) of PLK-cleaved LAP-TGF-β were associated with poor OS in patients with PDAC independent of age and stage (HR 2.57, 95% CI: 1.22−5.44, p = 0.0135). High levels of PLK-cleaved LAP-TGF-β were associated with high PRO-C3 and PRO-C6, indicating a relationship between the PLK-cleaved LAP-TGF-β fragment, TGF-β activity, and tumor fibrosis. If these preliminary results are validated, circulating PLK-cleaved LAP-TGF-β may be a biomarker for future clinical trials.
Collapse
Affiliation(s)
- Rasmus S. Pedersen
- Nordic Bioscience, 2730 Herlev, Denmark
- Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
- Correspondence:
| | | | | | | | | | | | | | - Hadi M. H. Diab
- Digestive Disease Center, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, 2400 Copenhagen, Denmark
| | - Lars N. Jorgensen
- Digestive Disease Center, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, 2400 Copenhagen, Denmark
| | - Carsten P. Hansen
- Department of Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Inna M. Chen
- Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, 2730 Herlev, Denmark
| | - Julia S. Johansen
- Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, 2730 Herlev, Denmark
- Department of Medicine, Herlev and Gentofte Hospital, University of Copenhagen, 2730 Herlev, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
| | | | | |
Collapse
|
2
|
Pedersen RS, Nissen NI, Jensen C, Thorlacius-Ussing J, Olesen ML, Langholm L, Jensen TM, Diab HM, Jørgensen LN, Karsdal M, Willumsen N. Abstract 1568: PLK activated TGF-β functions as a prognostic biomarker for patients with pancreatic ductal adenocarcinoma. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-1568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death with a 5-year survival rate of approximately 7%. Transforming growth factor beta (TGF-β) is highly involved in progression and metastasis in multiple cancers including PDAC. TGF-β is highly involved in tumor fibrosis and immune suppression, and several clinical trials are ongoing to evaluate anti-TGF-β therapies for treating patients diagnosed with cancer and for which biomarkers are key for success. TGF-β is produced in a latent complex with latency-associated protein (LAP), which needs to be cleaved by plasma kallikrein (PLK), releasing TGF-β to enable receptor binding and initiating of signaling. We developed a competitive enzyme-linked immunosorbent assay (ELISA) targeting PLK activated TGF-β and measured it in serum from patients with PDAC.
Methods: An ELISA based on monoclonal antibodies raised against the C-terminal side of the PLK cleavage site of TGF-β at R’58↓ was developed and validated for quantification of PLK activated TGF-β (L59TGF-β) in serum. To confirm that the ELISA was specifically measuring PLK cleaved TGF-β, L59TGF-β was measured in a TGF-β dilution after incubation with and without kallikrein. L59TGF-β was measured in pretreatment serum samples from patients with PDAC (n=39) and healthy controls (n=20). The prognostic value of L59TGF-β levels was examined with Kaplan-Meier analysis and evaluated for association with overall survival (OS) by multivariate cox regression analysis adjusted for age and cancer stage.
Results: L59TGF-β was only detected after incubation with kallikrein, demonstrating that the ELISA specifically detected kallikrein cleaved TGF-β. L59TGF-β was significantly elevated in patients with PDAC compared to healthy controls (p<0.0001). High levels of L59TGF-β (>median) were significantly associated with poor OS (HR: 2.71, 95%CI: 1.23-5.97, p=0.0135) in patients with PDAC, and median OS was 5.5 months (95%CI: 1.50-20.0) compared to 26.3 months (95%CI: 15.3-28.1) for patients with low levels of L59TGF-β. The association between high levels of L59TGF-β and poor OS remained statistically significant after adjusting for age and stage (HR: 2.33, 95%CI: 1.05-5.18, p=0.0372).
Conclusion: Quantification of PLK activated TGF-β (L59TGF-β) in serum predicted poor OS for patients with PDAC. The biomarker value of L59TGF-β should be validated and further investigated in a larger cohort to explore the clinical applicability of the biomarker.
Citation Format: Rasmus S. Pedersen, Neel I. Nissen, Christina Jensen, Jeppe Thorlacius-Ussing, Majken L. Olesen, Lasse Langholm, Tina M. Jensen, Hadi M. Diab, Lars N. Jørgensen, Morten Karsdal, Nicholas Willumsen. PLK activated TGF-β functions as a prognostic biomarker for patients with pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1568.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Hadi M. Diab
- 3Bispebjerg University Hospital, Copenhagen, Denmark
| | | | | | | |
Collapse
|
3
|
Karatt-Vellatt A, Laustsen AH, Masters EW, Oscoz S, Pus U, Knudsen C, Slavny P, Luther AM, Leah RA, Grifiths DT, Olesen ML, Lomonte B, Gutiérrez JM, McCafferty J. Harnessing phage display technology for generating fully human IgG antibodies that neutralise elapid neurotoxins. Toxicon 2019. [DOI: 10.1016/j.toxicon.2018.10.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Olesen ML, Madsen J. Boiling of strange quark matter in the early Universe: Strangeness conservation and nonequilibrium conditions. Phys Rev D Part Fields 1993; 47:2313-2323. [PMID: 10015822 DOI: 10.1103/physrevd.47.2313] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|